Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018
March 24, 2018 04:17 ET
|
Targovax ASA
Reference is made to the notice published on 15 March 2018 regarding the annual general meeting in Targovax ASA (the "Company") to be held on 11 April 2018 at 10:00 am (CEST). The proposal by the...
Alzheimer’s Virtual Reality Sensory Experience Featured at Upcoming ASA Workshop
March 23, 2018 09:31 ET
|
Alzheimer's Foundation of America
SAN FRANCISCO, March 23, 2018 (GLOBE NEWSWIRE) -- The Alzheimer’s Foundation of America (AFA)—in collaboration with Greener Media—is hosting a workshop titled, "What Would You Do: A Sensory...
Targovax ASA: Annual Report 2017
March 15, 2018 02:01 ET
|
Targovax ASA
On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual general meeting on 11 April 2018. The...
Targovax ASA: Notice of Annual General Meeting
March 15, 2018 02:01 ET
|
Targovax ASA
The Annual General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 11 April 2018 at 10:00 CET. Please find the notice including agenda for the General Meeting and...
Targovax ASA: Issuance of restricted stock unites (RSUs) to the chairman of the board of directors
March 01, 2018 01:00 ET
|
Targovax ASA
Reference is made to the extraordinary general meeting of Targovax ASA (the "Company") on 30 November 2017, where Patrick Vink was elected as chairman of the Company's board of directors and the...
Targovax to present at Biologics World Nordic 2018
February 27, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 27 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company will present at...
Targovax ASA: Fourth quarter and full year 2017 results
February 15, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017...
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
February 07, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 7 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces completion of the safety...
Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
February 06, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 6 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter 2018...
Targovax ASA: Exercise price of options
February 02, 2018 00:45 ET
|
Targovax ASA
With reference to the Stock exchange notification issued 1 February 2018 regarding options to employees: The exercise price of the granted options is NOK 17.17. The exercise price is equal to the...